Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Summary

The purpose of the study is to evaluate the efficacy and safety of LX101 in subjects with biallelic RPE65 mutation-associated inherited retinal dystrophy. This is an open-label, multicenter, randomized controlled Phase III clinical trial. Subjects were randomly assigned in a 1:1 ratio to either the intervention group or the control group. Subjects in the intervention group received subretinal injection of LX101, while those in the control group received no treatment.

Timeline

Start

2023-09-13

Primary completion

2025-08-13

Completion

2029-08

Drugs

Indications